Category: 3. Business

  • Perioperative Durvalumab Plus FLOT Generates OS Benefit in Gastric/GEJ Adenocarcinoma

    Perioperative Durvalumab Plus FLOT Generates OS Benefit in Gastric/GEJ Adenocarcinoma

    Treatment with the anti–PD-L1 monoclonal antibody durvalumab (Imfinzi) plus 5-fluorouracil-leucovorin-oxaliplatin-docetaxel (FLOT) produced a statistically significant and clinically meaningful improvement in overall survival (OS) among patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma vs placebo plus FLOT, regardless of pathological status, according to results from the phase 3 MATTERHORN trial (NCT04592913) presented during the 2025 ESMO Congress.1

    With a data cutoff date of September 1, 2025, the final OS analysis of the intention-to-treat population yielded a hazard ratio (HR) of 0.78 (95% CI, 0.63–0.96; P = .021) comparing the investigational arm with the control arm, with median OS not reached in either arm.

    “The OS results of the MATTERHORN study strongly support the use of durvalumab plus chemotherapy with FLOT as a new global standard of care for patients with localized, [resectable, gastric/GEJ] adenocarcinoma,” said Josep Tabernero, MD, PhD, professor of medicine, head of the Department of Medical Oncology at Vall d’Hebron University Hospital, and director of Vall d’Hebron Institute of Oncology, Barcelona, Spain, in his presentation.1

    Furthermore, a survival analysis stratified by demographic and clinical characteristics showed that OS improvement was consistent across most key subgroups. Notably, a similar improvement in OS was achieved regardless of PD-L1 status. In patients who were PD-L1-positive (PD-L1 TAP ≥1%), the HR was 0.79 (95% CI, 0.63–0.99), and the HR was 0.79 (95% CI, 0.41–1.50) in patients who were PD-L1-negative (PD-L1 TAP <1%), even demonstrating identical HRs across groups.

    Additional findings reported included an improvement in event-free survival (EFS), the study’s primary end point, among patients with any degree of pathological response and regardless of pathological nodal status at the time of the data cutoff on December 20, 2024.

    What Are the Study Design and Patient Characteristics?

    The phase 3 MATTERHORN trial is a global, randomized, double-blind, placebo-controlled study evaluating the efficacy of neoadjuvant-adjuvant durvalumab plus FLOT chemotherapy.2 The study’s primary end point is EFS; key secondary end points include OS and pathological complete response (pCR).

    The study population consists of 948 patients with localized gastric/GEJ adenocarcinoma who were treatment-naive upon enrollment. Patients were enrolled from across Asia, Europe, North America, and South America; of note, according Tabernero, is that 20% of patients were from Asia. Patients were stratified by geographical region, clinical lymph node status, and PD-L1 expression.

    For treatment, patients were randomly assigned 1:1 to receive either the durvalumab and FLOT combination or placebo plus FLOT (n = 474, both arms) in the neoadjuvant setting. Here, patients received their 1500 mg of their assigned treatment plus FLOT for 2 cycles before undergoing surgical resection 4 to 8 weeks after their last dose.3 Following surgical resection recovery, patients received 1500 mg of durvalumab or placebo as adjuvant therapy for up to 1 year.

    What Trial Data Have Been Previously Reported?

    In 2023, interim results with a data cutoff on February 1, 2023, suggested a significant and clinically meaningful benefit in pCR and near-PCR, with response rates of 27% and 14% observed in the investigational and control arms, respectively.4 Next, earlier in 2025, results of a primary end point analysis published in The New England Journal of Medicine revealed a 2-year EFS rate of 67.4% in the investigational arm vs 58.5% in the control arm.5 A consistent and manageable safety profile between arms was depicted in both reports.4,5

    Riding on the favorable efficacy and safety trends observed in previous analyses, this most recent readout highlights the potential of durvalumab and FLOT to become a new perioperative treatment option for patients.

    Disclosures: Tabernero declared a consulting role with Accent Therapeutics, Alentis Therapeutics, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Carina Biotech, Cartography Biosciences, Chugai Pharmaceutical, Daiichi Sankyo Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Genentech, Johnson & Johnson, Menarini Ricerche S.p.A, Merus N.V., MSD, Novartis, Ono Pharma USA, Peptomyc, Pfizer, Pierre Fabre, Quantro Therapeutics, Scandion Oncology, Scorpion Therapeutics, Servier, Sotio Biotech, Taiho Pharmaceutical, Takeda Pharmaceutical International AG, and Tolremo Therapeutics, and stocks with 1 TRIAL SP, Alentis Therapeutics, Oniria Therapeutics and Pangaea Oncology.

    References

    1. Tabernero, J. Final overall survival (OS) and the association of pathological outcomes with event-free survival (EFS) in MATTERHORN: A randomised, phase III study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric / gastroesophageal junction (G / GEJ) adenocarcinoma. Presented at: ESMO 2025 Congress; October 17–20, 2025; Berlin, Germany. Abstract LBA81.
    2. Assessing durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer. ClinicalTrials.gov. Updated April 3, 2025. Accessed October 17, 2025. https://clinicaltrials.gov/study/NCT04592913
    3. Janjigian YY, Van Cutsem E, Muro K, et al. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. Future Oncol. 2022;18(20):2465-2473. doi:10.2217/fon-2022-0093
    4. Janjigian YY, Al-Batran SE, Wainberg Za, et al. LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study. Ann Oncol. 2023;34:S1315-S1316. doi: 10.1016/j.annonc.2023.10.074
    5. Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. NEJM. 2025;393(3):217-230. doi: 10.1056/nejmoa2503701

    Continue Reading

  • US Dollar Forecast: DXY Volatility and Direction Hinge on FOMC, Data Gaps, Powell Guidance

    US Dollar Forecast: DXY Volatility and Direction Hinge on FOMC, Data Gaps, Powell Guidance

    Fed Meeting in Focus: Cut Likely, Guidance Will Drive Dollar Response

    Traders are now squarely focused on Wednesday’s FOMC rate decision and accompanying statement. While a quarter-point cut to a 3.75%–4.00% target range is fully priced in, market reaction will hinge on forward guidance and Chair Powell’s tone in the post-meeting press conference.

    With job growth slowing and inflation moderating, the Fed is under pressure to support labor conditions without reigniting price risks. The central bank’s challenge is compounded by limited data visibility, as the shutdown has delayed key labor and spending reports.

    If the Fed signals additional cuts are likely, that would increase downside pressure on the dollar. Conversely, any effort to downplay further easing could offer near-term support to the index.

    Treasury Yields Reflect Cautious Policy Outlook

    Bond markets echoed this sentiment shift. The benchmark 10-year yield retreated below 4% to close near 3.966%, while shorter maturities showed similar declines.

    With the Fed now weighing labor market deterioration more heavily than inflation risks, fixed income traders are positioning for a slower policy path through year-end. This cautious tone limited dollar upside, even as international rate expectations trended lower.

    Technical Picture: Tight Weekly Range Signals Impending Break

    Continue Reading

  • Assessing Valuation After Recent Share Price Volatility

    Assessing Valuation After Recent Share Price Volatility

    Rivian Automotive (RIVN) shares have seen some volatility recently, catching the attention of investors watching the electric vehicle sector. The company has delivered mixed short-term returns; however, its longer-term performance tells a different story.

    See our latest analysis for Rivian Automotive.

    After a choppy stretch this year, Rivian’s share price has recently lost momentum, sliding 16.7% over the past month. However, when you take a step back, the one-year total shareholder return is an impressive 24.2%, even after accounting for big swings since last year’s lows.

    If you’re curious what else is out there in electric vehicles and autos, now’s the perfect time to check out See the full list for free.

    But with Rivian’s shares now trading below analyst targets after a period of turbulence, the key question remains: is this a genuine buying opportunity, or has the market already factored in all the future growth?

    Rivian’s most widely followed narrative currently places its fair value at $14.48, which is about 10% above the last close of $12.98. This disconnect between the share price and narrative fair value sharpens focus on key drivers supporting this bullish view.

    Vertical integration in technology, especially in autonomy, battery, and software, combined with growing software and services revenue (including licensing via partnerships like with Volkswagen) is expected to open new high-margin revenue streams and diversify earnings. This could potentially strengthen EBITDA and net margins over time.

    Read the complete narrative.

    Want to know why high-tech partnerships and vertical integration are central to Rivian’s future? There’s a set of bold assumptions powering this target valuation, including game-changing revenue projections and margin shifts few expect. Curious about what the consensus is betting on beneath the surface? Unpack the narrative to see what’s driving the models and which financial levers matter most.

    Result: Fair Value of $14.48 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, persistent cash burn and policy changes, such as tariff shifts or tax credit reductions, could quickly undermine these optimistic forecasts for Rivian’s future.

    Find out about the key risks to this Rivian Automotive narrative.

    Looking at Rivian through the lens of price-to-sales, things appear less optimistic. The company’s ratio stands at 3.1x, which is quite a bit higher than both the US Auto industry average of 1.3x and the peer average of 1.5x. Even our fair ratio estimate is just 1.4x, suggesting the market is paying a premium. Does this premium signal belief in future breakthroughs or simply extra valuation risk?

    See what the numbers say about this price — find out in our valuation breakdown.

    NasdaqGS:RIVN PS Ratio as at Oct 2025

    If you see things differently or believe a deeper dive could reveal more, you can quickly assemble your own narrative and test your insights in just a few minutes. Do it your way

    A great starting point for your Rivian Automotive research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.

    Missing out on today’s real opportunities is easier than you think. Take action now and pinpoint your next investment edge. The Simply Wall Street Screener can help you target stocks with momentum, resilience, and breakthrough potential.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include RIVN.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • First Capital (FCAP) Margin Expansion Reinforces Bullish Community Bank Narrative

    First Capital (FCAP) Margin Expansion Reinforces Bullish Community Bank Narrative

    First Capital (FCAP) delivered impressive earnings growth of 25.1% over the last year, building on a five-year annualized growth rate of 4.9%. Net profit margins reached 31.2%, up from 28.7%, highlighting strong operational efficiency and high-quality earnings. The balance of risks and rewards currently leans positive, supported by ongoing profit growth and an attractive dividend.

    See our full analysis for First Capital.

    Next up, we will see how these results compare with the market’s prevailing narratives and whether the numbers reinforce or challenge the dominant stories about FCAP.

    Curious how numbers become stories that shape markets? Explore Community Narratives

    NasdaqCM:FCAP Earnings & Revenue History as at Oct 2025

    • Net profit margins advanced to 31.2%, up from 28.7% last year. This signals a tangible step up in operational efficiency for First Capital and offers investors increased confidence in the company’s core profitability.

    • Strong earnings quality and margin growth provide reassurance around the bank’s ability to sustain reliable profits.

      • This margin expansion supports the view that community banks like FCAP offer a safe and reliable source of yield, especially when larger institutions face greater volatility.

      • With margins climbing higher, the underlying quality of FCAP’s earnings now sits in rare territory among regional banks.

    • FCAP trades at a Price-To-Earnings (P/E) ratio of 9.8x, noticeably under the US Banks industry average of 11.2x and the peer group’s 10.8x. This positions its shares as attractively valued within its sector.

    • Shares changing hands at a discount highlight a compelling mismatch between FCAP’s recent profit gains and the lower market valuation being assigned.

      • Investors who focus on value strategies may find FCAP especially interesting, given its below-industry-average P/E alongside high and rising net profit margins.

      • Despite ongoing operational improvements, the gap between its current share price of $42.92 and DCF fair value of $72.33 suggests room for re-rating if positive trends continue.

    • The latest filing noted no material risks, leaving the positive balance of risks and rewards unchanged since the last update.

    • Market watchers point to the current environment with solid profit growth, an attractive dividend, and no flagged risks, favoring a steady outlook for the stock.

      • Investors are likely to focus now on whether these supportive conditions can be maintained, as stability often attracts long-term capital to regional banks like FCAP.

      • The absence of new concerns removes a common hurdle, giving recent positive fundamentals more room to influence sentiment and valuation.

    Continue Reading

  • Hong Kong start-up Stellerus eyes world’s first supply of 3D wind data via satellites

    Hong Kong start-up Stellerus eyes world’s first supply of 3D wind data via satellites

    Hong Kong University of Science and Technology (HKUST) start-up Stellerus Technology aims to be the world’s first provider of satellite-enabled three-dimensional wind data to help wind power, transport and insurance firms boost revenues, cut costs and manage risks, according to its founders.

    Stellerus, founded in 2023 by the university’s academics, would leverage China’s cost competitiveness in satellite manufacturing to make global 3D wind data collection economically viable, said Su Hui, the chairwoman and co-founder.

    3D wind data – wind direction and speed and their changes with altitude – is crucial for improving weather forecasting, especially severe climate events.

    “After I came to Hong Kong, I realised the technology for implementing such a project in mainland China was quite developed and the cost would be much lower than overseas,” Su said. “In the US, such a satellite could cost US$100 million to build, compared with 20 million yuan [US$2.8 million] in China.”

    Su Hui, the chairwoman and co-founder of Stellerus Technology. Photo: Edmond So

    Su, a hydraulic expert, joined the HKUST’s department of civil and environmental engineering in 2022 as chair professor. She was formerly a principal scientist and weather programme manager at the Jet Propulsion Laboratory at Nasa.

    Continue Reading

  • South Korea auto-parts maker Kapec Valeo fined for technology misappropriation | MLex

    ( October 26, 2025, 03:00 GMT | Official Statement) — MLex Summary: South Korean auto-parts maker Kapec Valeo has been fined 410 million won ($285,000) by the country’s competition regulator for technology misappropriation, in violation of the Subcontracting Act. The Korea Fair Trade Commission said the company used an improved design proposal from its subcontractor without consent, incorporated it into its own design drawings and shared it with rival suppliers. The subcontractor had originally modified the design while producing a prototype to address qualify defects in the company’s earlier design. The KFTC also said that Kapec Valeo, a joint venture between Korea Powertrain and French automotive supplier Valeo Bayen, requested 198 technical documents from six subcontractors without issuing the required written statements outlining the purpose and ownership of the requested data, as mandated under the law. The regulator said the case marks the first case where an engineering change request was recognized as a protected technical material, noting that the technical data cannot be used or shared without explicit consent. The statement, in Korean, is attached….

    Prepare for tomorrow’s regulatory change, today

    MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.

    Know what others in the room don’t, with features including:

    • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
    • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
    • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
    • Curated case files bringing together news, analysis and source documents in a single timeline

    Experience MLex today with a 14-day free trial.

    Continue Reading

  • Rio Tinto mine in Mongolia probes corruption allegations

    Rio Tinto mine in Mongolia probes corruption allegations

    A Rio Tinto-controlled company in Mongolia has asked police to help with a “comprehensive internal investigation” into allegations of misconduct and corruption.

    Oyu Tolgoi LLC, which is 66 per cent owned by Rio and owns the Oyu Tolgoi copper mine, confirmed the investigation was underway after Mongolian media reported that police had raided the homes of some employees in the procurement division.

    Loading…

    Continue Reading

  • Exploring Valuation After Recent Share Price Gains

    Exploring Valuation After Recent Share Price Gains

    Trimble (TRMB) shares edged slightly higher this week, gaining about 1% over the past seven days. The stock has posted a strong 34% total return over the past year, reflecting sustained investor interest in the company’s performance.

    See our latest analysis for Trimble.

    Momentum seems to be building for Trimble as its recent 5.2% seven-day share price return adds to an impressive 33.7% total shareholder return over the past year. The stock’s latest moves suggest investors are increasingly optimistic about its longer-term growth outlook.

    If these positive trends have you thinking bigger, now could be the perfect time to discover fast growing stocks with high insider ownership.

    With shares climbing and fundamentals looking solid, investors face a classic dilemma: is Trimble still undervalued today, or has the recent rally already captured the company’s growth prospects, leaving limited upside from here?

    Trimble’s most widely followed narrative suggests the company’s fair value lands well above its recent close, pointing to continued upside in the eyes of analysts. The current gap between the share price and narrative valuation hints at a belief in ongoing growth and resilience despite sector headwinds.

    Accelerating adoption of AI-enabled, cloud-based solutions (such as ProjectSight, autonomous procurement, and analytics in project management and transportation) is increasing customer value and workflow integration. This trend supports higher recurring software revenues and improved net margins. The migration from hardware-focused, CapEx models to bundled, subscription-based offerings, even in traditionally hardware-oriented segments, expands the addressable market, improves revenue visibility, and increases the recurring revenue mix. This drives greater predictability and enhanced long-term earnings.

    Read the complete narrative.

    Want to see which assumptions power this valuation? Discover why analysts think Trimble’s subscription model and digital transformation could reshape its growth profile. See the key ingredients behind this bold price target and decide if the narrative aligns with your outlook.

    Result: Fair Value of $97.70 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, persistent macroeconomic headwinds or stalled adoption of Trimble’s subscription offerings could undermine these bullish expectations and slow the company’s progress.

    Find out about the key risks to this Trimble narrative.

    Looking at Trimble’s valuation through the lens of its price-to-earnings multiple provides a much less optimistic picture. At 67.6x, it is far above both its peers (44.8x) and the industry average (25.9x), as well as the 36.1x fair ratio the market might eventually demand. That premium signals potential valuation risk if expectations fall short. Is the market pricing in too much growth already?

    See what the numbers say about this price — find out in our valuation breakdown.

    NasdaqGS:TRMB PE Ratio as at Oct 2025

    If you see things differently or want to dive into the numbers yourself, you can craft a personal Trimble narrative in just a few minutes. Do it your way.

    A great starting point for your Trimble research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

    Thousands of investors use Simply Wall St to spot unique ideas. Don’t let others get ahead while you wait. Your ideal investment could be just one click away.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include TRMB.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Assessing Valuation After New AI-Focused Data Center Launches and Tech Innovations

    Assessing Valuation After New AI-Focused Data Center Launches and Tech Innovations

    Jabil (JBL) turned heads at the OCP Global Summit by launching its new J-422G server, along with several other AI and cloud-focused data center solutions. The company highlighted modular server expansion and reinforced its commitment to secure, AI-driven innovation.

    See our latest analysis for Jabil.

    Jabil’s share price has surged nearly 49% since the start of the year, supported recently by fresh AI and cloud-focused product launches, executive board news, and sizable buyback activity. Even more impressive, its total return to shareholders is up over 70% in the past 12 months and a remarkable 554% over five years. This reflects growing optimism around the company’s evolving portfolio and long-term strategy.

    If these milestones have you thinking about what else is gaining momentum in tech and AI, exploring See the full list for free. could reveal your next opportunity.

    Yet with a meteoric share-price rise and strong buyback momentum, investors face a key question: is Jabil’s upside still ahead, or has the market already accounted for every sign of future growth?

    With Jabil’s last close at $212.44, the most popular narrative places fair value higher, at $247.38. This suggests considerable upside remains if the narrative’s assumptions take shape. Here’s what underpins this outlook and what could change the story.

    Jabil’s significant U.S. manufacturing footprint positions it well to benefit from potential tariff changes, allowing it to maintain and possibly grow revenue through strategic relocation of manufacturing activities. The expansion in India, particularly in Gujarat, to support photonics capabilities indicates growth potential in a promising market, likely enhancing future revenues from domestic demand and infrastructure projects.

    Read the complete narrative.

    Want to know the math behind that bullish target? The narrative is built on aggressive forecasts for future profit margins and rapid expansion into new markets. Which assumptions fuel that lofty price? You’ll have to explore the full narrative to see the growth bets and the bold moves baked into this fair value.

    Result: Fair Value of $247.38 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, continued weakness in electric vehicles and renewable energy, or persistent inventory pressures, could still challenge Jabil’s growth story in the future.

    Find out about the key risks to this Jabil narrative.

    Looking at Jabil through its price-to-earnings ratio, the stock trades at 34.5 times earnings. This figure is above the US electronics industry average of 25.9 and just under its fair ratio of 35.4. While this might suggest the shares are on the expensive side, being close to the fair ratio could also mean the market is pricing in Jabil’s growth plans. Is there real upside left, or could expectations be running ahead of reality?

    See what the numbers say about this price — find out in our valuation breakdown.

    NYSE:JBL PE Ratio as at Oct 2025

    Curious to see if your perspective matches the analysis or if another angle stands out? Exploring the data yourself takes just a few minutes, so why not Do it your way

    A great starting point for your Jabil research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.

    Sharpen your investing toolkit and seize today’s hottest opportunities. Act now, or you could miss out on strategies others are already using for growth.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include JBL.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Exploring Pitney Bowes (PBI) Valuation After Strong Recent Share Price Gains

    Exploring Pitney Bowes (PBI) Valuation After Strong Recent Share Price Gains

    Pitney Bowes (PBI) shares have seen some movement lately, attracting attention among investors curious about the factors shaping the stock’s recent performance. While there is no headline event this week, valuation and past returns remain top of mind.

    See our latest analysis for Pitney Bowes.

    Pitney Bowes has enjoyed a remarkable run, with the share price climbing 63% year-to-date and delivering a massive 70% total return over the past year. That kind of momentum, supported by strong multi-year gains, suggests investors see real upside potential or shifting risk perceptions around the company.

    If you’re interested in seeing what else is catching attention right now, this could be the perfect moment to broaden your perspective and discover fast growing stocks with high insider ownership

    With shares trading well below analyst price targets and solid returns posted over several years, the big question for investors is whether Pitney Bowes is still undervalued or if the company’s future growth is already fully reflected in its current price.

    With Pitney Bowes closing at $11.77, the most widely followed market narrative points to a fair value of $17. This suggests current prices could be lagging future expectations. This creates an intriguing disconnect that is rooted in technology-driven transformation and bold operational ambitions.

    Ongoing investments in digital transformation, operational efficiencies, and automation, supported by a leadership team focused on efficiency, are expected to yield further improvements in net margins and free cash flow through cost reductions and modernization. These initiatives may enhance long-term earnings power.

    Read the complete narrative.

    Want to know why some believe Pitney Bowes’ future is brighter than ever? The narrative teases potential profit growth, meaningful margin expansion and shrinking share counts. Interested in the assumptions driving this projected shift? Uncover the financial blueprint underpinning that fair value.

    Result: Fair Value of $17 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, shrinking demand for physical mail and rising competition in logistics could challenge Pitney Bowes’ future growth if new initiatives do not succeed.

    Find out about the key risks to this Pitney Bowes narrative.

    If you see the story differently or want to map out your own view, it’s quick and simple to build your take on the numbers. Do it your way.

    A great starting point for your Pitney Bowes research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.

    Expand your investment toolkit right now. Go beyond the obvious and access smart opportunities that many overlook. These tailored stock screens could be your next winning edge.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include PBI.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading